Intravenous glial‐derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Gene Medicine

• Publication date

  2008-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/jgm.1152PMID 18085726
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease?

  2007cited by this paper
• Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes

  2007cited by this paper
• Nurr1 is phosphorylated by ERK2 in vitro and its phosphorylation upregulates tyrosine hydroxylase expression in SH-SY5Y cells.

  2007cited by this paper
• Humanization of anti‐human insulin receptor antibody for drug targeting across the human blood–brain barrier

  2007cited by this paper
• Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson’s disease

  2007cited by this paper
• Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.

  2006cited by this paper
• Decline in Exogenous Gene Expression in Primate Brain Following Intravenous Administration Is Due to Plasmid Degradation

  2006cited by this paper
• Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study

  2005cited by this paper
• Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease

  2005cited by this paper
• Organ‐specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice

  2004cited by this paper
• Normalization of Striatal Tyrosine Hydroxylase and Reversal of Motor Impairment in Experimental Parkinsonism with Intravenous Nonviral Gene Therapy and a Brain-Specific Promoter

  2004cited by this paper
• A rapid assay for glial cell line-derived neurotrophic factor and neurturin based on transfection of cells with tyrosine hydroxylase promoter-luciferase construct.

  2003cited by this paper
• Timecourse of striatal re‐innervation following lesions of dopaminergic SNpc neurons of the rat

  2003cited by this paper
• Glial cell line-derived neurotrophic factor does not enter normal mouse brain

  2003influential reference
• The human tyrosine hydroxylase gene promoter.

  2003cited by this paper
• Gene targeting in vivo with pegylated immunoliposomes.

  2003cited by this paper
• Global non-viral gene transfer to the primate brain following intravenous administration.

  2003cited by this paper
• Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer.

  2003cited by this paper
• Cloning and cell type-specific regulation of the human tyrosine hydroxylase gene promoter.

  2003cited by this paper
• Intravenous Nonviral Gene Therapy Causes Normalization of Striatal Tyrosine Hydroxylase and Reversal of Motor Impairment in Experimental Parkinsonism

  2003cited by this paper
• Marked dopaminergic cell loss subsequent to developmental, intranigral expression of glial cell line-derived neurotrophic factor.

  2002cited by this paper
• Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer.

  2002cited by this paper
• Receptor-Mediated Gene Targeting to Tissues In Vivo Following Intravenous Administration of Pegylated Immunoliposomes

  2001cited by this paper
• Brain-specific expression of an exogenous gene after i.v. administration

  2001cited by this paper
• Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

  2000cited by this paper
• Transcriptional and Posttranscriptional Control of Tyrosine Hydroxylase Gene Expression During Persistent Stimulation of Pituitary Adenylate Cyclase‐Activating Polypeptide Receptors on PC12 Cells: Regulation by Protein Kinase A‐Dependent and Protein Kinase A‐Independent Pathways

  1998cited by this paper
• Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.

  1997cited by this paper
• Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery

  1997cited by this paper
• 5' upstream DNA sequence of the rat tyrosine hydroxylase gene directs high-level and tissue-specific expression to catecholaminergic neurons in the central nervous system of transgenic mice.

  1994cited by this paper
• Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo

  1994cited by this paper
• GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.

  1993cited by this paper
• Tissue-specific and high-level expression of the human tyrosine hydroxylase gene in transgenic mice.

  1991cited by this paper
• Adrenergic, cholinergic, and inactive human neuroblastoma cell lines with the action-potential Na+ ionophore.

  1977cited by this paper

• Recent advances in potential drug nanocarriers for CNS disorders: a review

  2025cites this paper
• Role and mechanism of molecular hydrogen in the treatment of Parkinson’s diseases

  2025cites this paper
• Protective Effect of Whey Protein Supplement Against Rotenone Induced Motor Dysfunction in a Rat Model of Parkinson Disease

  2024cites this paper
• Brain-on-a-chip: an emerging platform for studying the nanotechnology-biology interface for neurodegenerative disorders

  2024cites this paper
• Lipid-based nanoparticles for drug delivery in Parkinson’s disease

  2024cites this paper
• Designing and Formulation of Nanocarriers for "Alzheimer's and Parkinson's" Early Detection and Therapy.

  2024cites this paper
• Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review

  2024cites this paper
• A comprehensive and updated review on the applications of vesicular drug delivery systems in treatment of brain disorders: A shelter against storms

  2023cites this paper
• Treatment of Parkinson’s disease with biologics that penetrate the blood–brain barrier via receptor-mediated transport

  2023cites this paper
• A Historical Review of Brain Drug Delivery

  2022cites this paper
• Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease.

  2022cites this paper
• Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases.

  2022cites this paper
• Recent developments and applications of smart nanoparticles in biomedicine

  2022cites this paper
• The role of lipid based nanoparticles in brain targeted drug delivery system: An overview

  2022cites this paper
• Nanomedicines for Brain Drug Delivery

  2021cites this paper
• Biomaterials and stem cells as drug/gene delivery vehicles for Parkinson's treatment: an update.

  2021cites this paper
• Nanomaterials as novel agents for amelioration of Parkinson’s disease

  2021cites this paper
• Growth Factor Therapy for Parkinson’s Disease: Alternative Delivery Systems

  2021cites this paper
• Highly Specific Blood-Brain Barrier Transmigrating Single-Domain Antibodies Selected by an In Vivo Phage Display Screening

  2021cites this paper
• Smart Nanoparticles in Biomedicine: An Overview of Recent Developments and Applications

  2021cites this paper
• Liposomes vs Phytosomes: Principles, Methodologies, and Therapeutic Applications with Emphasis on CNS Disorders

  2020cites this paper
• Interplay of BDNF and GDNF in the Mature Spinal Somatosensory System and Its Potential Therapeutic Relevance

  2020cites this paper
• Liposomes as Brain Targeted Delivery Systems

  2020cites this paper
• Liposomes: Novel Drug Delivery Approach for Targeting Parkinson's Disease.

  2020cites this paper
• Novel Diagnostic and Therapeutic Immunologic Strategies to Overcome Infectious, Oncologic and Neurodegenerative Disorders

  2020cites this paper
• Membrane Fluidity as a New Mean to Selectively Target Cancer Cells with Fusogenic Lipid Carriers.

  2020cites this paper
• Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain

  2020influential citation
• Key for crossing the BBB with nanoparticles: the rational design

  2020cites this paper
• Therapeutic Nanoparticles and Their Targeted Delivery Applications

  2020cites this paper
• Surface engineered liposomal delivery of therapeutics across the blood brain barrier: recent advances, challenges and opportunities

  2019cites this paper
• Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies.

  2019cites this paper
• Nanodelivery of therapeutic agents in Parkinson's disease.

  2019cites this paper
• Multifunctional Nanoparticles for Successful Targeted Drug Delivery across the Blood-Brain Barrier

  2018cites this paper
• Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.

  2018cites this paper
• Current development of nanocarrier delivery systems for Parkinson's disease pharmacotherapy

  2018cites this paper
• Chapter 8 Liposomal Drug Delivery to the Central Nervous System

  2018cites this paper
• Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer's disease

  2017cites this paper
• Nanobiomaterials’ applications in neurodegenerative diseases

  2017cites this paper
• The Effects of Glial Cell Line-Derived Neurotrophic Factor after Spinal Cord Injury

  2017cites this paper
• Potential Gene Therapy Towards Treating Neurodegenerative Disea ses Employing Polymeric Nanosystems.

  2017cites this paper
• Colloids for drug delivery to the brain

  2017cites this paper
• Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment

  2017cites this paper
• Liposomal Drug Delivery to the Central Nervous System

  2017cites this paper
• For Drug Discovery Today Title : Targeting Delivery in Parkinson ’ s Disease

  2017cites this paper
• Feasibility of Three‐Dimensional Placement of Human Therapeutic Stem Cells Using the Intracerebral Microinjection Instrument

  2016cites this paper
• Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

  2016influential citation
• Transferrin-modified liposome promotes α-mangostin to penetrate the blood-brain barrier.

  2016cites this paper
• Targeting delivery in Parkinson's disease.

  2016cites this paper
• Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.

  2016cites this paper
• Towards a Better Treatment Option for Parkinson’s Disease: A Review of Adult Neurogenesis

  2016cites this paper
• Potential use of nanomedicines for drug delivery across the BBB in health and diseased brain.

  2016cites this paper
• Nanoparticle transport across the blood brain barrier

  2016cites this paper
• Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease

  2016cites this paper
• Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.

  2016cites this paper
• Prospects for polymer therapeutics in Parkinson's disease and other neurodegenerative disorders

  2015cites this paper
• Extracellular vesicles and their synthetic analogues in aging and age-associated brain diseases

  2015cites this paper
• Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders

  2015cites this paper
• GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson’s disease

  2015cites this paper
• Neurotrophin delivery using nanotechnology.

  2013cites this paper
• Nanomedicine in cerebral palsy

  2013cites this paper
• Biomaterial approaches to gene therapies for neurodegenerative disorders of the CNS.

  2013cites this paper
• Tumor Imaging and Interferon-γ–Inducible Protein-10 Gene Transfer Using a Highly Efficient Transferrin-Conjugated Liposome System in Mice

  2013cites this paper
• Synthetic nucleic acids delivered by exosomes: a potential therapeutic for generelated metabolic brain diseases

  2013influential citation
• Microspheres for targeting delivery to brain

  2013cites this paper
• Trojan horse at cellular level for tumor gene therapies.

  2013cites this paper
• Lipid Nanoparticles for the Delivery of Nucleic Acids

  2013cites this paper
• GDNF gene delivery via a 2-(dimethylamino)ethyl methacrylate based cyclized knot polymer for neuronal cell applications.

  2013cites this paper
• From Molecular to Nanotechnology Strategies for Delivery of Neurotrophins: Emphasis on Brain-Derived Neurotrophic Factor (BDNF)

  2013cites this paper
• Investigational surgical therapies

  2013cites this paper
• Gene therapy for Parkinson’s disease: state-of-the-art treatments for neurodegenerative disease

  2013cites this paper
• Nanoparticles for sensing and potential gene therapy in neuroscience

  2012cites this paper
• Gene Therapy for Parkinson's Disease

  2012cites this paper
• Targeted blood-to-brain drug delivery --10 key development criteria.

  2012cites this paper
• Neurotrophic factors and neurodegenerative diseases: a delivery issue.

  2012cites this paper
• Therapeutics, imaging and toxicity of nanomaterials in the central nervous system.

  2012cites this paper
• Rosette Nanotubes for Targeted Drug Delivery

  2012cites this paper
• Towards New Therapies for Parkinson's Disease

  2011cites this paper
• Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumption

  2011cites this paper
• Repairing the parkinsonian brain with neurotrophic factors.

  2011cites this paper
• GDNF and PD: Less Common Points of View

  2011cites this paper
• In vivo real-time fluorescence visualization and brain-targeting mechanisms of lipid nanocarriers with different fatty ester:oil ratios.

  2011cites this paper
• Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model.

  2010cites this paper
• Non-viral gene delivery carrier and its three-dimensional transfection system.

  2010cites this paper
• A Comparative Study of Transfection Efficiency between Liposomes, Immunoliposomes and Brain-specific Immunoliposomes

  2010cites this paper
• Transcriptional targeting to brain cells: Engineering cell type-specific promoter containing cassettes for enhanced transgene expression.

  2009cites this paper
• Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells

  2009cites this paper
• A modified protocol for efficient DNA encapsulation into pegylated immunoliposomes (PILs).

  2009cites this paper
• Aplicações de técnica estereotáctica para a neurocirurgia molecular: uma revisão

  2009cites this paper
• Receptor-mediated therapeutic transport across the blood-brain barrier.

  2009cites this paper
• Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier.

  2009cites this paper
• Neuroprotection in a 6‐hydroxydopamine‐lesioned Parkinson model using lactoferrin‐modified nanoparticles

  2009cites this paper
• Differential receptor-mediated drug targeting to the diseased brain

  2009cites this paper
• Brain-Targeting Mechanisms of Lactoferrin-Modified DNA-Loaded Nanoparticles

  2009cites this paper
• Near Complete Rescue of Experimental Parkinson’s Disease with Intravenous, Non-viral GDNF Gene Therapy

  2009cites this paper
• Aptamers for in vivo applications

  2008cites this paper
• Driving GDNF expression: the green and the red traffic lights.

  2008influential citation
• Advances in the development of siRNA-based therapeutics for cancer.

  2008cites this paper